Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018 by Eyre, David W. et al.
                          Eyre, D. W., Town, K., Street, T., Barker, L., Sanderson, N., Cole, M. J., ...
Fifer, H. (2019). Detection in the United Kingdom of the Neisseria
gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate
resistance to azithromycin, October to December 2018. Eurosurveillance,
24(10), [1900147]. https://doi.org/10.2807/1560-
7917.ES.2019.24.10.1900147
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.2807/1560-7917.ES.2019.24.10.1900147
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via ECDC at
https://doi.org/10.2807/1560-7917.ES.2019.24.10.1900147 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1www.eurosurveillance.org
Rapid communication
Detection in the United Kingdom of the Neisseria 
gonorrhoeae FC428 clone, with ceftriaxone resistance 
and intermediate resistance to azithromycin, October to 
December 2018
David W Eyre1,2, Katy Town³, Teresa Street², Leanne Barker², Nicholas Sanderson², Michelle J Cole³, Hamish Mohammed³, Rachel 
Pitt³, Maya Gobin³, Charles Irish³, Daniel Gardiner³, James Sedgwick³, Charles Beck³, John Saunders³, Deborah Turbitt³, Clare 
Cook³, Nick Phin³, Bavithra Nathan3,5, Paddy Horner3,4,5, Helen Fifer3,5
1. Big Data Institute, University of Oxford, Oxford, United Kingdom
2. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
3. National Incident Management Team, Public Health England, London, United Kingdom
4. Population Health Sciences, University of Bristol, Bristol, United Kingdom
5. These authors contributed equally to this work
Correspondence: David W Eyre (david.eyre@bdi.ox.ac.uk)
Citation style for this article: 
Eyre David W, Town Katy, Street Teresa, Barker Leanne, Sanderson Nicholas, Cole Michelle J, Mohammed Hamish, Pitt Rachel, Gobin Maya, Irish Charles, Gardiner 
Daniel, Sedgwick James, Beck Charles, Saunders John, Turbitt Deborah, Cook Clare, Phin Nick, Nathan Bavithra, Horner Paddy, Fifer Helen. Detection in the United 
Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Euro 
Surveill. 2019;24(10):pii=1900147. https://doi.org/10.2807/1560-7917.ES.2019.24.10.1900147 
Article submitted on 22 Feb 2019 / accepted on 06 March 2019 / published on 07 March 2019
We describe detection in the United Kingdom (UK) 
of the drug-resistant  Neisseria gonorrhoeae  FC428 
clone, with ceftriaxone resistance and intermediate 
azithromycin resistance. Two female patients devel-
oped infection following contact with UK-resident men 
from the same sexual network linked to travel to Ibiza, 
Spain. One case failed treatment with ceftriaxone, 
and azithromycin and gentamicin, before successful 
treatment with ertapenem. Both isolates had indistin-
guishable whole-genome sequences. Urgent action is 
essential to contain this drug-resistant strain.
Antimicrobial resistance in Neisseria gonorrhoeae  is a 
major public health concern, in particular resistance to 
ceftriaxone which is the last available drug for empiri-
cal monotherapy for gonorrhoea. Here, we report fur-
ther international spread of the N. gonorrhoeae FC428 
clone associated with ceftriaxone resistance and 
intermediate resistance to azithromycin.
The FC428 clone was first isolated in Japan in January 
2015 [1], with a second isolate, FC460, obtained from 
the same patient [2]. This clone was subsequently 
reported in 2017 in Australia (A7536, A7846) [3], Canada 
(47707) [4], Denmark (GK124) [5] and France (F90) [6], 
and in 2018 in Ireland (IR72) [7]. However despite this 
global dissemination, sustained local transmission has 
not been reported to date. We describe a transmis-
sion cluster that probably involved at least four peo-
ple resident in the United Kingdom (UK). We report the 
clinical management, microbiology and whole-genome 
sequencing findings.
 
Case descriptions
Case 1, a female patient, presented to a sexual health 
clinic in the UK in October 2018 with urinary symptoms. 
She had had unprotected vaginal intercourse with 
more than one male partner, 2 months before presen-
tation, while on holiday in Ibiza, Spain. These partners 
were normally resident in the UK. The patient had a 
positive N. gonorrhoeae nucleic acid amplification test 
(NAAT) and endocervical culture. Before the results of 
susceptibility testing were available, she was treated 
empirically, in line with national treatment guidelines 
at the time, with a single dose of intramuscular ceftri-
axone 500 mg and oral azithromycin 1 g. A NAAT test of 
cure (TOC) 2 weeks after treatment was negative. We 
were unable to trace her partners.
Case 2, a female patient, presented to another sexual 
health clinic elsewhere in the UK in November 2018 
for an asymptomatic sexual health screen. Two weeks 
previously, she had had unprotected vaginal, oral and 
anal sex with an asymptomatic UK-resident man who 
had been in Ibiza and had links with the same sexual 
network as Case 1. She had positive vaginal and rec-
tal  N. gonorrhoeae  NAAT results, a negative throat  N. 
gonorrhoeae  NAAT and was culture-negative at all 
three sites. She was treated empirically 1 week later 
with a single dose of intramuscular ceftriaxone 1 g 
and at this visit reported rectal symptoms. She initially 
responded clinically but her symptoms relapsed, and 
she was culture-positive on a vaginal sample taken 10 
days later by her general practitioner, and culture and 
NAAT-positive at both the rectum and urogenital tract 
but not the throat when she attended the sexual health 
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clinic a further 4 days later for treatment. She failed 
subsequent treatment with single dose intramuscu-
lar gentamicin 240 mg plus oral azithromycin 2 g but 
cleared the infection with intravenous ertapenem 1 g 
once daily for 3 days. A NAAT TOC taken 2 weeks later 
was negative at both sites.
The male sexual contact of Case 2 tested negative 
for gonorrhoea on urine NAAT testing in November 
2018 without treatment and he did not report symp-
toms before or after sexual intercourse with Case 2. 
However, given his link to the same sexual network as 
Case 1, he is likely to have been the source of Case 2’s 
infection, and to have spontaneously cleared his infec-
tion [8]. Further information on other partners of Case 
2’s male contact was not available. Case 2 also had 
unprotected oral sex and protected vaginal sex with a 
new male partner 8 days after receiving the first treat-
ment (ceftriaxone), before her symptoms relapsed. This 
partner subsequently tested  N. gonorrhoeae  NAAT-
positive at the pharynx but had a negative pharyngeal 
culture and negative urine NAAT. Although this case 
may have had pre-existing asymptomatic pharyngeal 
carriage, we considered that his positive test was pos-
sibly explained by acquisition of  N. gonorrhoeae  from 
Case 2. He was therefore also treated with intravenous 
Figure 1
Ceftriaxone-resistant Neisseria gonorrhoeae isolates (n=15), including from Case 1 and Case 2, United Kingdom, 2018
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ertapenem 1 g once daily for 3 days and had a negative 
TOC 2 weeks later.
Phenotypic characterisation
One N. gonorrhoeae  isolate from each culture-positive 
case (Case 1: H18-209 and Case 2: H18-502) was sent to 
Public Health England’s national reference laboratory 
for characterisation. Antimicrobial susceptibility 
testing was undertaken using minimum inhibitory 
concentration (MIC) gradient diffusion strips. Results 
were interpreted using European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) break-
points [9].
Both isolates showed resistance to ceftriaxone (MIC 
1.0 mg/L), cefixime (MIC 2.0 mg/L), penicillin (MIC 
2.0 mg/L), tetracycline (MIC 2.0 mg/L) and ciprofloxa-
cin (MIC > 32 mg/L), and intermediate resistance to 
Figure 2
Time-dated Bayesian phylogeny of Neisseria gonorrhoeae FC428 clone cases and epidemiological details, 2015–2019 (n = 10)
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azithromycin (MIC 0.5 mg/L). The isolates were sus-
ceptible to spectinomycin (MIC 8.0 mg/L) and did not 
produce a β-lactamase. MICs for gentamicin and ertap-
enem were 4.0 mg/L and 0.032 mg/L, respectively, 
which represent low values likely to be susceptible 
although no formal breakpoints are defined.
Genomic characterisation
Whole genome sequencing (WGS) was undertaken using 
Illumina MiSeq and Oxford Nanopore Technologies 
(ONT) sequencing as previously described [10]. Raw 
sequence reads are available under NCBI BioProject 
PRJNA523794. Maximum likelihood phylogenies [11], 
based on mapping to the NCCP11945 reference genome, 
and corrected for recombination [12], were used to com-
pare the sequences of the cases’ isolates to previously 
described ceftriaxone-resistant isolates [1-7,10,13-15].
Antimicrobial resistance determinants were identi-
fied from ONT and Illumina data as described previ-
ously, using a combination of de novo assembly and 
mapping-based approaches [16]. BEAST v1.10.4 [17] 
was used to generate time-dated phylogenies using a 
recombination-corrected whole genome alignment and 
a Hasegawa-Kishino-Yano (HKY) substitution model. A 
strict molecular clock was fitted. As there were a lim-
ited number of genomes, the prior distribution for the 
clock rate was chosen to match the credibility inter-
val for the  N. gonorrhoeae  mutation rate determined 
previously [18]. Outputs from three independent chains 
were merged after checking for convergence and a suf-
ficient effective sample size.
The two isolates’ genomes were indistinguishable 
and were from multilocus sequence typing (https://
pubmlst.org/neisseria) ST-1903, N. gonorrhoeae multi-
antigen sequence typing (NG-MAST;  http://www.
ng-mast.net) ST-1614 (porB  1053,  tbpB  33) and  N. 
gonorrhoeae  sequence typing for antimicrobial 
resistance (NG-STAR; https://ngstar.canada.ca) ST233. 
The  penA  allele was identical to that seen in FC428 
(penA-60.001), containing two key ceftriaxone resist-
ance mutations, A311V and T483S, as well as G545S, 
I312M and V316T. There were no 23S rRNA mutations; 
azithromycin intermediate resistance was conferred 
by an mtrR promoter deletion (−35A) and ciprofloxacin 
resistance by  parC  S87R and  gyrA  S91F and D95A 
substitutions.
Comparison with previously sequenced ceftriaxone-
resistant isolates demonstrated the cases’ isolates 
were from the FC428 clone (Figure 1).
A time-dated Bayesian phylogeny of all available 
sequences from the FC428 clone is shown in Figure 2, 
with published details of the location of each case’s 
country of residence and sexual contacts. The cur-
rent cases’ genomes are most closely related to F90; 
both the present culture-positive patients and the 
F90 patient had not travelled outside of Europe; their 
sexual contacts were, respectively, in Spain (with 
men from the UK) and in France. The remainder of the 
cases were diagnosed globally (Ireland, Japan, Canada, 
Denmark, Australia), however, all had had sexual con-
tacts in Asia.
Within the FC428 clone, after correction for recombi-
nation, 267 unique single nucleotide polymorphisms 
(SNPs) were identified among the genomes. Such 
diversity makes direct transmission between any of the 
previously described cases unlikely, with the excep-
tion of GK124 and 47707 which were genetically indis-
tinguishable. To our knowledge, this link has not been 
previously reported. These isolates from Denmark 
and Canada were from a man and a woman who both 
reported sexual contact in China with a member of the 
opposite sex.
Based on previously determined rates of  N. gonor-
rhoeae evolution, the date of the most recent common 
ancestor of the FC428 clone was estimated as October 
2001 (95% highest posterior density interval: May 1999 
to March 2004). This is considerably before the first 
reported case from the clone, FC428, in January 2015. 
This suggests the clone emerged and persisted in a 
setting where antimicrobial susceptibility testing for N. 
gonorrhoeae  is not routinely undertaken. This allowed 
it to remain undetected for probably more than 10 years 
and enabled the emergence of diversity in the infection 
reservoir with which each of the reported cases has 
separately come into contact.
Discussion
There is growing evidence that the FC428 clone has 
the potential to spread globally, which is of concern 
given it is resistant and intermediate resistant to the 
only two remaining empirical treatment options for  N. 
gonorrhoeae, ceftriaxone and azithromycin. Although 
reported new cases are uncommon and mostly 
described following sexual contact in South East Asia, 
our cases, with the previously reported F90 case, pro-
vide evidence of transmission occurring within Europe. 
As the transmission between our cases is likely to have 
occurred between UK residents visiting Ibiza, a well-
known European party destination, there is a risk that 
further undetected transmission has occurred.
The location of the sexual contacts of the remaining 
cases described within the clone, suggests South East 
Asia or China, is the likely reservoir for this clone. There 
is therefore an urgent need for improved access in the 
region to N. gonorrhoeae diagnostics and antimicrobial 
resistance detection [19]. This is required for surveil-
lance so that the burden of antimicrobial resistance 
can be better quantified and rational antibiotic treat-
ment guidelines made. At the level of the individual 
patient, it is needed to prevent onward transmission of 
drug-resistant gonorrhoea.
We report a  N. gonorrhoeae  transmission cluster 
involving the FC428 clone with two confirmed female 
cases and at least two probable additional infections in 
the male partners of the cases. Given that the partners 
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of Case 1 could not be contacted and that it is unclear 
how long the asymptomatic male contact of Case 2 was 
infected [8,20] and unclear if this N. gonorrhoeae strain 
was initially acquired by UK residents before or during 
travel to Ibiza, it is likely that there has been onward 
transmission from one or more undetected cases. 
As a result, Public Health England have introduced 
enhanced monitoring of data submitted by local labo-
ratories on  N. gonorrhoeae  antimicrobial resistance 
to ensure all ceftriaxone-resistant isolates identified 
are sent to Public Health England for confirmation and 
investigation promptly to help reduce further spread.
Case 2 required treatment with 3 days of intravenous 
ertapenem after failed treatment with ceftriaxone, 
and with azithromycin and gentamicin. However, wide-
spread use of ertapenem may pose logistical difficul-
ties where sexual health services are not set up to 
administer intravenous therapy on consecutive days. In 
addition, use of carbapenems may promote drug resist-
ance in other organisms, including Enterobacteriaceae, 
where carbapenems are usually reserved for multid-
rug-resistant infections. Therefore, new treatments 
for  N. gonorrhoeae  infection are urgently required. 
Zoliflodacin is a novel antibiotic active against urogeni-
tal infections, but with only limited efficacy in pharyn-
geal infections [21]. Several other potential agents are 
under development [22].
European public health agencies and sexual health 
clinicians should be aware that the FC428 clone has 
potential to spread in Europe. This threatens the effec-
tiveness of gonorrhoea treatment. New treatments are 
required that are effective against all infected sites 
and can be delivered by existing sexual health infra-
structure. Ongoing surveillance of antimicrobial resist-
ance with culture or emerging molecular methods 
[23], test of cure, extra-genital sampling and effective 
partner notification are vital to maintain control of  N. 
gonorrhoeae.
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